InvestorsHub Logo
Followers 18
Posts 108
Boards Moderated 0
Alias Born 01/30/2018

Re: None

Thursday, 05/08/2025 10:22:53 AM

Thursday, May 08, 2025 10:22:53 AM

Post# of 431694
Interesting Find

Well as this board has been lacking for pertinent information recently, I figured I would post something that could positively impact our little Elite, in the space of ADHD medicine. It has come to my attention that there could be a huge shift away from the ADHD medicine Strattera as Eli Lilly has just announced they made a business decision to discontinue manufacturing the product. A little history as to why this is occurring potentially. Several years ago scientists found that nitrosamines are potentially cancer causing and if anyone remembers Zantac made with Ranitidine was pulled from the shelves. Well this was because the Ranitidine molecule has an amine group that could potentially form the Nitrosamine. Fast forward to what I recently am seeing is that the FDA is placing limits on the Atomoxetine ie Strattera molecule that I don't think the manufacturers want to deal with the exposure. Additionally, Glenmark just recalled all of their product in February 2025. This is a $300-400M market, that people are going to have to shift to another ADHD medicine and luckily Elite makes 2 of them that they will probably shift to in Adderall and Vyvanse. Just wanted to share some information with the board. Cheers to all.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News